Boston Scientific Corporation logo

Boston Scientific Corporation (BSX)

Market Closed
16 Oct, 08:00 PM
NYSE NYSE
$
44. 38
+0.24
+0.5551%
After Hours
$
44. 72
+0.34 +0.7548%
62.49B Market Cap
74.55 P/E Ratio
- Div Yield
10.65M Volume
2.01 Eps
$ 44.14
Previous Close
Add Transaction
Day Range
43.89 44.83
Year Range
41.39 105.65
Want to track BSX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue?

Boston Scientific (BSX) Up 3.3% Since Last Earnings Report: Can It Continue?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 year ago
Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?

Is it Worth Retaining Boston Scientific Stock in Your Portfolio Now?

Investors continue to be optimistic about BSX, courtesy of its international expansion efforts and strategic acquisitions.

Zacks | 1 year ago
Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript)

Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript)

Boston Scientific Corporation (NYSE:BSX ) Bank of America's 2025 Health Care Conference May 13, 2025 11:00 AM ET Company Participants Daniel Brennan - EVP & CFO Joe Fitzgerald - EVP & Group President, Cardiology Conference Call Participants Travis Steed - Bank of America Travis Steed All right. Good morning, everybody.

Seekingalpha | 1 year ago
Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock

Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock

Zacks.com users have recently been watching Boston Scientific (BSX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 1 year ago
These 3 Stocks Soared Following Strong Quarterly Results

These 3 Stocks Soared Following Strong Quarterly Results

The 2025 Q1 earnings cycle is in full swing. And these three companies posted results that had investors pleased.

Zacks | 1 year ago
Earnings Season: 3 Companies Raising Guidance

Earnings Season: 3 Companies Raising Guidance

Raising guidance? In this uncertainty?

Zacks | 1 year ago
EMEA Growth & Product Launches to Support Boston Scientific Stock

EMEA Growth & Product Launches to Support Boston Scientific Stock

Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.

Zacks | 1 year ago
Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?

Wall Street Analysts Think Boston Scientific (BSX) Is a Good Investment: Is It?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Zacks | 1 year ago
Here is Why Growth Investors Should Buy Boston Scientific (BSX) Now

Here is Why Growth Investors Should Buy Boston Scientific (BSX) Now

Boston Scientific (BSX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks | 1 year ago
Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know

Boston Scientific (BSX) Upgraded to Buy: Here's What You Should Know

Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks | 1 year ago
Here's Why Boston Scientific (BSX) is a Strong Momentum Stock

Here's Why Boston Scientific (BSX) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 year ago
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?

Here is how Boston Scientific (BSX) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Zacks | 1 year ago
Loading...
Load More